Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
Microvascular Therapeutics Selected to Present Investment Opportunity at ACQUICON 2026
Microvascular Therapeutics, Inc. (“MVT”), a clinical-stage biotechnology company developing next-generation ultrasound imaging and therapeutic technologies, today announced that it has been selected to present in the ACQUICON 2026 Deal Room on Tuesday, October 20, 2026, from 12:30–1:30 p.m. Mountain Time at the Karen Gail Miller Conference Center in Salt Lake City. - October 14, 2026 - Microvascular Therapeutics, Inc.
THROMBOLEX Announces Interim RAPID-PE Results
THROMBOLEX Announces Interim RAPID-PE Results Showing Favorable Safety and Reproducible Multicenter Results in Acute Pulmonary Embolism. Mechanically channeled thrombolysis procedure disrupts and dissolves thrombus in a single on-the-table session. - October 05, 2026 - Thrombolex, Inc.
ALS TDI to Convene ALS Research, Industry, and Community Leaders at 2026 Summit and White Coat Affair Gala
This October, two Boston events will bring people together to share research updates, build connections, and accelerate progress for people with ALS. - September 23, 2026 - ALS Therapy Development Institute
SignaBlok Awarded NIH NIDDK Grant to Develop Novel TREM-1 Antagonist Drug for Inflammatory Bowel Disease
SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD. - September 18, 2026 - SignaBlok, Inc.
Rob Merrill Named CEO of TFives, Life Sciences AI Compliance
TFives appoints 25-year healthcare regulatory veteran as CEO to lead enterprise adoption of compliance-ready AI governance for the Life Sciences industry. - September 17, 2026 - TFives
Microvascular Therapeutics Appoints George Kokke to Board of Directors
Veteran family office executive and healthcare investor brings more than 30 years of investment, finance, and board experience. - September 17, 2026 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Appoints Charles Garrison, MD, to Scientific Advisory Board
Dr Charles Garrison, an experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development as new Scientific Advisory Board member. - September 14, 2026 - Microvascular Therapeutics, Inc.
MVT Nanobubbles Enable Non-Thermal Focused Ultrasound Ablation in Preclinical Brain Tumor Study
University of Utah researchers use MVT-101 phase-shift nanobubbles with focused ultrasound and MRI to confirm treatment location - September 14, 2026 - Microvascular Therapeutics, Inc.
Kepon Biotech Addresses Global Biopharma Supply‑Chain Pain Points with China‑Based One‑Stop Procurement System
Kepon Biotech is a Chinese one‑stop supply‑chain partner for life‑science clients. It resolves procurement challenges: scattered suppliers, complex cross‑border compliance, variable batch quality and long lead‑times. It provides consolidated sourcing, special‑goods compliance, graded cold‑chain logistics and global certifications for cell lines, culture media, LAL reagents and clinical materials, delivering streamlined, low‑risk procurement for pharma, IVD, CRO/CDMO and research institutes. - September 07, 2026 - Shanghai Kepon Biotech Co., Ltd.
Asclepii Selected to Exhibit Poseidon at Vizient Innovative Technology Exchange
Asclepii will showcase its FDA 510(k)-cleared Poseidon™ Nanosilver Hydrogel at Vizient’s Innovative Technology Exchange in Las Vegas on September 24, marking an important milestone in the company’s commercial expansion and bringing its wound care technology to healthcare leaders across Vizient’s network. - September 04, 2026 - Asclepii
Helix BioMedix Completes $2 Million Private Placement to Advance Xeroderma Pigmentosum Development Program
Financing strengthens balance sheet and accelerates advancement of proprietary DNA repair technology targeting UV-induced DNA damage. - August 29, 2026 - Helix BioMedix, Inc
VMRD Launches Rapid Horse-Side Insulin Test to Decrease Risk of Laminitis in Metabolic Horses
VMRD, Inc. is thrilled to share the launch of their exciting new test for horse-side measurement of insulin in horses. Run on the same palm-sized reader as VMRD SAA and Foal IgG, this highly portable multi-functional testing platform embodies VMRD’s vision of improving animal health through... - August 28, 2026 - VMRD, Inc.
Kepon Biotech Launches Integrated Cross‑Border Risk‑Control Solutions for Global Cell Culture Media Trade
Kepon Biotech handles import‑export for fermentation, research and GMP clinical‑grade cell culture media. It addresses cross‑border risks such as bioactivity degradation, complex global regulations and customs detention. With EAC, REACH, FDA, TGA, PMDA, CMDCAS and Halal credentials, it delivers grade classification, global certification, light‑shielded cold‑chain logistics and multilingual customs documents for global CDMOs, biomanufacturers and research labs. - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross‑Border Solutions for Global Spermidine Procurement
Kepon Biotech provides multi‑grade spermidine and spermidine trihydrochloride for food, pharma, cosmetics and life‑science research. It mitigates cross‑border risks such as oxidative degradation, complex certification rules and HS misclassification. Backed by EAC, REACH, FDA and Halal credentials, it delivers one‑stop certification, nitrogen‑sealed temperature‑controlled logistics and multilingual customs documents for manufacturers, labs and distributors across EAEU, EU, U.S. and Middle‑East. - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches One-Stop Cross-Border Compliance & Logistics Solutions for Life Science Reagents
Kepon Biotech provides a one-stop global compliance and supply system for life science procurement. It solves core cross-border challenges including complex customs clearance, unstable cold-chain logistics, fragmented regional regulations. The company offers standardized biochemical reagents, reference standards and cell culture media, with full compliance support and segmented temperature-controlled logistics, delivering reliable, low-risk sourcing for global labs and pharmaceutical manufacture - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross‑Border Export Solutions for Global LAL Endotoxin‑Testing Reagent Procurement
Kepon Biotech delivers factory‑sourced LAL endotoxin‑testing kits for biopharma, vaccine and medical‑device clients. Working with ISO13485‑certified manufacturers, it provides regional compliance paperwork, 2‑8°C cold‑chain logistics and low‑MOQ trial orders across CIS, Southeast Asia, Middle East, EU and North America. Its one‑stop export solution fixes customs detention, reagent deactivation and raw‑material stock‑out risks for 1000+ users in 50+ countries. - August 18, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Unveils Full-Link Risk Control & Compliance Solutions for Global Cell Culture Media Trade
Global labs and biopharma firms encounter common cell culture media procurement risks: inconsistent batches, customs delays, cold chain product inactivation and inflexible high MOQs. Shanghai Kepon Biotech releases a full cross-border supply solution and procurement risk guide, offering flexible samples, one-stop biological goods clearance and segmented cryogenic logistics for global cell research, biotech and diagnostic manufacturers. - August 18, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Comprehensive Cross-Border Procurement & Risk Control Solutions for Industrial Fine Chemicals
Global factories, energy plants and research labs run into widespread procurement risks for industrial chemicals: inconsistent purity, hazardous goods customs blockages, failed long-distance shipping, rigid high MOQs and incomplete compliance documents. Shanghai Kepon Biotech releases an integrated cross-border supply system and complete pitfall guide, providing flexible trial orders, one-stop chemical customs agency and dedicated hazardous cold chain logistics for biotech, pharmaceutical. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross-Border Procurement and Risk Control Solutions for High-Purity Organic & Inorganic Chemicals
Global labs and pharma face organic & inorganic chemical procurement risks including unstable purity, customs detention, failed shipping, high MOQs and incomplete SDS docs. Shanghai Kepon Biotech releases a cross-border supply & risk guide with flexible samples, full chemical clearance and custom cold chain logistics for life science and new energy industries. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Shanghai Kepon Biotech Launches Full Risk-Control Cross-Border Solutions for Certified Reference Standards Procurement
Global labs, pharma and food testers face China reference standards cross-border risks: poor batch traceability, customs delays, rigid MOQs, cold chain breakdowns and missing COA/SDS. Shanghai Kepon Biotech offers integrated supply, special goods clearance and segmented cold chain for life science, new energy and food testing industries. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Food Safety Standards Raw Material Procurement Solutions & Risk Avoidance Guide Released by Shanghai Kepon Biotech for Global Food Testing & Food Manufacturing Plants
Global food manufacturers and third-party food testing labs face severe procurement risks for food safety reference standards: inconsistent batch purity, cross-border food regulatory document gaps, strict customs inspection, high MOQ limits and incomplete compliance certification. Shanghai Kepon Biotech launches integrated cross-border supply system, one-stop food safety filing and traceable certified standards for food testing, beverage and food processing industries worldwide. - August 16, 2026 - Shanghai Kepon Biotech Co., Ltd.
New 2026 Report Reveals an AI/LLM Gap Between Biopharma Sponsors and Their CROs/Vendors
Life Science Strategy Group looks beyond frontier-AI hype to show how biopharma teams use AI and LLMs in daily work, and where their CRO and vendor partners are falling short. 71% of sponsors rate their own AI/LLM output highly. Only 27% say the same of their CROs and vendors. - August 12, 2026 - Life Science Strategy Group, LLC
DNA Harvest Partners and ToolGen Announce Strategic Partnership to Accelerate AI-Guided Predictive Breeding for Gene-Edited Crops
DNA Harvest Partners Pte. Ltd. (DNAHP), one of the world's most advanced AI-guided predictive breeding companies, and ToolGen, a global leader in CRISPR-Cas9 gene editing technology, today announced a strategic partnership to accelerate the development of superior rapeseed (Brassica napus)... - August 11, 2026 - DNA Harvest Partners Pte. Ltd.
ecotera health Submits Decentralized Urine Microplastics / Nanoplastics Observational Study for IRB Review
Study will evaluate an at-home approach to longitudinal microplastics / nanoplastics monitoring in urine using the EcoExposure™ platform - August 08, 2026 - ecotera health
New York Cancer & Blood Specialists Welcomes Hematologist-Oncologist Dr. David Drory
New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, proudly announces the addition of Dr. David Drory to its team of dedicated medical oncologists and hematologists. Beginning August 3, 2026, Dr. Drory will be practicing at NYCBS’s office... - August 04, 2026 - New York Cancer & Blood Specialists
Microvascular Therapeutics Highlights the Future of Ultrasound Theranostics in Comprehensive Wiley Review
Microvascular Therapeutics, Inc. (MVT) today announced publication of a comprehensive review in Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (WIREs Nanomedicine and Nanobiotechnology), a leading peer-reviewed journal with a 2025 Journal Impact Factor of 8.6, entitled,... - July 28, 2026 - Microvascular Therapeutics, Inc.
New York Cancer & Blood Specialists Opens New State-of-the-Art Cancer Center in Lake Success
New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, is proud to announce the opening of its new comprehensive cancer center at 3 Dakota Drive, Lake Success, NY 11042. The location will open to patients on July 13, 2026, and replaces its previous... - July 10, 2026 - New York Cancer & Blood Specialists
Hemanext Expands Commercial Footprint Through Strategic Partnership with OneBlood
Hemanext Inc. announced a strategic production partnership with OneBlood, one of the nation's largest independent blood centers, marking a significant milestone in Hemanext's commercial expansion and accelerating adoption of Hemanext ONE® across the United States. - July 06, 2026 - Hemanext
Cancer Survivor Expands Scottsdale Wellness Center with Advanced Recovery Therapies
A Scottsdale-based wellness center is expanding its offerings with a combination of advanced, non-invasive therapies designed to support individuals navigating cancer, Lyme disease, neurological conditions, and chronic pain. The Shift Healing and Wellness in North Scottsdale is bringing together technologies rarely found in one place - including a motorized rehabilitation system (the Quadriciser), oxygen therapy, and red light therapy - with a personalized, whole-body approach to care. - June 25, 2026 - The Shift Healing and Wellness
Alera Bio Appoints David McCullough as Chief Executive Officer
Alera Bio announced the appointment of David McCullough as Chief Executive Officer. An experienced biotechnology executive, McCullough will lead corporate strategy, financing, organizational development, and execution of the company’s clinical and regulatory roadmap. He will oversee advancement of AB-101, Alera’s novel therapy for MCT-8 deficiency, as the company works to bring new hope to patients and families affected by this devastating rare neurodevelopmental disorder. - June 04, 2026 - Alera Bio
SPARK Industries Announces New MRI Signal Analysis Platform for Neurological Disease and Cancer Research
SPARK Industries announced advancements in its patent-pending MRI signal-analysis platform designed to detect previously unresolved neurological and structural signatures within raw MRI data. Internal validation across 1,000+ clinical MRI cases involving TBI, Alzheimer’s, Parkinson’s, and prostate cancer demonstrated consistent signal relationships associated with known disease states. SPARK is now pursuing blinded third-party validation trials. - May 27, 2026 - SPARK Industries Corporation
O∆K Names Mareham Yacoub 2026 National Leader of the Year for Service to Campus and Community
Mareham Yacoub Awarded 2026 Omicron Delta Kappa National Leader of the Year for Service to Campus and Community - May 20, 2026 - Omicron Delta Kappa
Asclepii Partners with Nottingham Spirk to Scale Breakthrough Regenerative Wound Care Technology Nationwide
Strategic collaboration aims to expand access to next-generation regenerative platform designed to improve healing outcomes and reduce the cost of chronic wound care. - May 06, 2026 - Asclepii
Thrombolex Announces Enrollment of 100th Patient in RAPID-PE Clinical Study
Thrombolex, Inc., today announced the enrollment of the 100th patient in the RAPID-PE clinical study. This significant milestone underscores the growing clinical confidence in the BASHIR® Endovascular System and the urgency of generating robust evidence for the treatment of intermediate-risk pulmonary embolism (PE). - April 30, 2026 - Thrombolex, Inc.
Parvus Therapeutics Initiates First-in-Human Clinical Trial of PVT401 for Inflammatory Bowel Disease
PVT401, a peptide-MHC nanomedicine, is the second Parvus drug candidate to enter clinical trials. - April 30, 2026 - Parvus Therapeutics U.S., Inc.
Aldevron Named 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy Category
Aldevron has been recognized as a 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy category. The CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect, are widely regarded as one of the most credible benchmarks of CDMO performance in the biopharma industry. Now in their 15th year, the awards are based entirely on verified feedback. - April 14, 2026 - Aldevron
Alera Bio Announces Exclusive Licensing Agreement with BLA Technology to Expand Thyroid Hormone Intellectual Property Portfolio
Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. - April 09, 2026 - Alera Bio
Alera Bio Appoints Andrew Eisen, MD, PhD, as Chief Scientific Officer
Alera Bio has appointed Andrew Eisen, MD, PhD, as Chief Scientific Officer, bringing over 20 years of experience in translational medicine and clinical development. With deep expertise in neuroscience, metabolic disease, and myelination, Dr. Eisen will lead the advancement of Alera’s lead program, AB-101, and help drive its mission to develop transformative therapies for patients with severe neurological disorders, including MCT-8 deficiency. - April 08, 2026 - Alera Bio
Brain Healing, Inc. Receives FDA Humanitarian Use Device (HUD) Designation for MELAS
Non-invasive biophoton platform advances toward HDE pathway for rare mitochondrial disease - April 01, 2026 - Tesla BioHealing, Inc.
PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS
PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. - March 31, 2026 - ALS Therapy Development Institute
AkrivisBio Inc., a New and Original Manufacturer of Metabolic Assay Kits
AkrivisBio is a provider of assay kits for the life science and biotechnology industries. AkrivisBio products include a variety of chemical, biochemical and enzyme activity assays as well as cell proliferation and toxicity assays, sample isolation and preparation kits, and staining kts. The kits... - March 29, 2026 - AkrivisBio
SignaBlok Receives Orphan Drug Designation from FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurity
SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide... - March 27, 2026 - SignaBlok, Inc.
Medical Industry Websites Compete for Digital Excellence in the WebAwards
The Web Marketing Association has opened entries for the 30th Annual WebAward Competition, inviting hospitals, medical practices, and healthcare organizations worldwide to compete for recognition as the best medical websites of 2026. Websites will be evaluated on design, innovation, usability, and technology. Winners gain industry recognition and valuable benchmarking insights. Entry deadline: May 29, 2026. - March 27, 2026 - Web Marketing Association
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
• In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy - March 26, 2026 - SignaBlok, Inc.
Poriferous, LLC Announces Publication of U.S. Patent Application for Dura-Bloc™ Technology
Poriferous, LLC today announced that the United States Patent and Trademark Office (USPTO) has published U.S. patent application US-20230165682-A1, covering their Dura-Bloc™ Patient Specific Cranial Implants. The publication of this patent application further reinforces Poriferous' standing... - March 19, 2026 - Poriferous, LLC
Thrombolex, Inc. Secures $50 Million Series A Growth Financing
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML). Thrombolex, a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed, with strong support from current investors and co-founders. - March 16, 2026 - Thrombolex, Inc.
RX Japan's INTERPHEX WEEK TOKYO 2026 Releases Conference Program Featuring 320 Sessions Across Manufacturing, Quality, CMC, and Digital Transformation
The full conference program for INTERPHEX WEEK TOKYO 2026, Japan’s largest pharma and biotech gathering has been officially published ahead of the event taking place May 20 (Wed)–22 (Fri), 2026 at Makuhari Messe in Chiba, Japan, bringing together an expected 950 exhibitors and 35,000... - March 16, 2026 - RX
Hemanext ONE® Receives 510(k) Clearance for Expanded Indications for Use in the United States
Hemanext Inc. today announced that the Hemanext ONE® System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded indications for use in the United States. The expanded Indications for Use enable processing of whole blood and apheresis-derived AS-3 leukocyte-reduced red blood cells. - March 10, 2026 - Hemanext
POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test
POM Health Systems, a cancer screening service offering oncologist-led subscription cancer screening plans, today announced that it has reached an agreement with GRAIL, Inc., to offer its Galleri® multi-cancer early detection (MCED) test. Under the terms of the agreement, POM will deploy the... - March 05, 2026 - POM Health Systems
Interphex Week Tokyo to Expand Its 2026 Showcase as Japan’s Largest Pharma and Biotech Gathering
INTERPHEX WEEK TOKYO 2026, one of Japan’s largest and most influential trade shows for the pharmaceutical and biotechnology sectors, is set to return May 20–22 at Makuhari Messe with an expanded showcase expected to surpass its 2025 performance and deliver a more dynamic experience for... - February 26, 2026 - RX